 | Up a level |
Journal Article
Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Kueemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Nitz, Ulrike Anneliese (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J. Clin. Oncol., 35 (26). S. 3046 - 3057. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755